You are here: Home » Current Affairs » Coronavirus » News
Business Standard

Bharat Biotech's Covaxin succeeds in challenge trials on Rhesus monkeys

The results showed protective efficacacy, increasing Sars-CoV-2 specific IgG and neutralising antibodies reducing the replication of the virus in the nasal cavity, throat and lung tissues of monkey

Topics
Coronavirus Vaccine | Bharat Biotech | Monkey

Sohini Das  |  Mumbai 

Covaxin, bharat biotech, covid, coronavirus, vaccine, drugs, medicine, pharma
Bharat Biotech noted on its website that the vaccine was given (as a two dose vaccination regimen) to 20 rhesus macaques who were divided into four groups.

Hyderabad-based has released the data from the animal trials of its vaccine candidate, which showed that Covaxin was able to generate 'robust immune responses'.

The firm said that the vaccine prevented infection and disease in the primates upon high amounts of exposure to live virus Sars-CoV-2. This is called a challenge trial where a participant is exposed deliberately to the pathogen after being given the vaccine shot.

The company tweeted "proudly announces the animal study results of Covaxin–-these results demonstrate the protective efficacy in a live viral challenge model."

The indigenously-developed vaccine by and the Indian Council of Medical Research (ICMR), the country's apex health research organisation. It is now undergoing trials at 12 sites across India.

ALSO READ: Halting Oxford's Covid-19 vaccine trial is not a setback; it shows prudence

Bharat Biotech noted on its website that the vaccine was given (as a two dose vaccination regimen) to 20 rhesus macaques who were divided into four groups. One group was given placebo, while three groups were immunised with three different vaccine candidates at zero and 14-days. "All the macaques were exposed to viral challenge 14 days after the second dose," the company said.

The results showed protective efficacy, increasing Sars-CoV-2 specific IgG and neutralising antibodies reducing the replication of the virus in the nasal cavity, throat and lung tissues of the monkeys. Bharat Biotech also noted that no evidence of pneumonia was observed in the vaccinated groups unlike the placebo group. "Adverse events were not seen in animals immunized with a two-dose vaccination regimen," it added.

Summary of the outcomes:

. A 2-dose vaccination regimen of inactivated SARS-CoV-2 vaccine candidates was administered in 20 rhesus macaques (divided into four groups equally)

.

One group was given placebo, while three groups were immunised with 3 different vaccine candidates at zero and 14 days

. All the macaques were exposed to viral challenge 14 days after the second dose

. The results showed protective efficacy, increasing SARS-CoV-2 specific IgG and neutralising antibodies

. Reduced replication of the virus in the nasal cavity, throat, and lung tissues of monkey

. No evidence of pneumonia was observed in vaccinated groups, unlike the placebo group

. Adverse events were not seen in animals immunised with a two-dose vaccination regimen

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Sat, September 12 2020. 14:25 IST
RECOMMENDED FOR YOU